Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Jumps 5.2% – Here’s Why

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)’s share price traded up 5.2% during mid-day trading on Friday. The company traded as high as $8.09 and last traded at $8.2150. Approximately 433,505 shares changed hands during trading, an increase of 11% from the average session volume of 389,977 shares. The stock had previously closed at $7.81.

Top Eupraxia Pharmaceuticals Stories

Investors following EPRX have been watching these stories:

• Positive Sentiment: HC Wainwright kept its Buy rating and $16 price target, raising its estimates for fiscal 2026 and 2028 and moving its 2030 forecast from a loss to a profit. HC Wainwright estimate updates
• Neutral Sentiment: Interim results from Eupraxia’s Phase 2b eosinophilic esophagitis (EoE) trial are expected in December, creating a key upcoming clinical catalyst. Q3 results and trial update timing
• Negative Sentiment: HC Wainwright lowered its fiscal 2027 and 2029 EPS forecasts, while the company reported a wider third-quarter loss—risks that temper the positive analyst news. Analyst estimates Quarterly loss report

Analysts Set New Price Targets

EPRX has been the subject of a number of analyst reports. Wedbush began coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. Royal Bank Of Canada initiated coverage on Eupraxia Pharmaceuticals in a research note on Monday, November 9th. They set an “outperform” rating and a $14.00 price objective on the stock. Stifel Nicolaus set a $25.00 price objective on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Eupraxia Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 12.25 and a quick ratio of 16.00. The firm has a fifty day moving average of $7.64 and a two-hundred day moving average of $7.24. The stock has a market capitalization of $548.01 million, a P/E ratio of -7.69 and a beta of 1.04.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.03. On average, analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.86 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

Large investors have recently made changes to their positions in the business. Affinity Asset Advisors LLC grew its position in shares of Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after acquiring an additional 1,289,005 shares during the period. Jupiter Topco LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $6,851,000. Seven Fleet Capital Management LP acquired a new position in Eupraxia Pharmaceuticals in the 1st quarter worth about $5,137,000. Redmile Group LLC acquired a new position in Eupraxia Pharmaceuticals in the 1st quarter worth about $5,068,000. Finally, Rubric Capital Management LP acquired a new position in Eupraxia Pharmaceuticals in the 1st quarter worth about $5,004,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company’s lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.